Case study: treatment of a 76-year-old male patient with right anterior tibial and tibio-peroneal trunk occlusions using the Ranger™ Drug-Coated Balloon

Click here to get access to the full-length case study video now.

Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.


New 3-year data presented on the MAJESTIC trial; review of several challenging case studies; and more in the CIRSE Drug Eluting Symposium.
 

Prefer to read the study highlights?  Read the updated MAJESTIC 3-year data (DES) and 12-month Ranger Registry (DCB).


Did you know Did you know

DID YOU KNOW

Boston Scientific is the only company investing in a complete portfolio of Drug-Eluting Therapies.

Products Overview

ELUVIATM Drug-Eluting
Vascular Stent System

The Eluvia Drug-Eluting Stent delivers unprecedented results in the SFA through its unique SUSTEND™ drug-delivery
technology.

MAJESTIC Trial MAJESTIC Trial

RANGERTM Paclitaxel-Coated
PTA Balloon Catheter

The Ranger Drug Coated balloon has been designed to provide consistent and predictable drug delivery through efficient drug transfer and a strong coating integrity.

RANGER SFA RCT RANGER SFA RCT